Journey Medical (US:DERM) ZACKSยท2025-05-14 22:10Group 1 - Journey Medical Corporation reported a quarterly loss of $0.18 per share, better than the Zacks Consensus Estimate of a loss of $0.24, and an improvement from a loss of $0.53 per share a year ago, representing an earnings surprise of 25% [1] - The company posted revenues of $13.14 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 10.55%, and showing a slight increase from $13.03 million in the same quarter last year [2] - Journey Medical shares have increased approximately 61.6% since the beginning of the year, significantly outperforming the S&P 500's gain of 0.1% [3] Group 2 - The earnings outlook for Journey Medical is mixed, with the current consensus EPS estimate for the coming quarter at -$0.12 on revenues of $15.1 million, and -$0.41 on revenues of $68.24 million for the current fiscal year [7] - The Medical - Drugs industry, to which Journey Medical belongs, is currently ranked in the top 29% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]